Mach F, Baigent C, Catapano AL, et al. ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;2019(290):140–205.

Article  Google Scholar 

European Atherosclerosis Society. Strategies for the prevention of coronary heart disease: a policy statement of the European Atherosclerosis Society. Eur Heart J. 1987;1:77–88.

Google Scholar 

Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis. 1994;110:121–61.

Article  PubMed  Google Scholar 

Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.

Google Scholar 

Taylor F, Huffman MD, Macedo AF et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013; 2013(1):CD004816.

PubMed  PubMed Central  Google Scholar 

Rea F, Savaré L, Corrao G, Mancia G. Adherence to Lipid-Lowering Treatment by Single-Pill Combination of Statin and Ezetimibe. Adv Ther. 2021;38:5270–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Averna M, Banach M, Bruckert E et al. Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis. 2021;325:99–109.

Article  CAS  PubMed  Google Scholar 

Ray KK, Troquay RPT, Visseren FLJ et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4‑year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 2023;11:109–19.

Article  CAS  PubMed  Google Scholar 

Landmesser U, Chapman MJ, Stock JK, et al. Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart J. 2017;2018(39):1131–43.

Google Scholar 

Laufs U, Banach M, Mancini GBJ, et al. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. J Am Heart Assoc. 2019;8(7):e011662.

Article  PubMed  PubMed Central  Google Scholar 

Goldberg AC, Leiter LA, Stroes ESG et al. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. JAMA 2019; 322: 1780–1788.

Wang Y, Nichol MB, Yan BPY, Wu J, Tomlinson B, Lee VWY. Descriptive analysis of real-world medication use pattern of statins and antiplatelet agents among patients with acute coronary syndrome in Hong Kong and the USA. Bmj Open. 2019;9:e24937.

Article  PubMed  PubMed Central  Google Scholar 

Katzmann JL, Sorio-Vilela F, Dornstauder E et al. Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL‑C. Clin Res Cardiol. 2022;111:243–52.

Article  CAS  PubMed  Google Scholar 

Stone NJ, Robinson JG, Lichtenstein AH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the american college of cardiology/american heart association task force on practice guidelines. Circulation. 2013;2014(129):1–45.

Google Scholar 

Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J. 1998;19:1434–503.

Article  Google Scholar 

De Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Atherosclerosis. 2004;173:379–89.

Article  Google Scholar 

Eliasson M, Janlert U, Jansson J‑H, Stegmayr B. Time trends in population cholesterol levels 1986–2004: influence of lipid-lowering drugs, obesity, smoking and educational level. The northern Sweden MONICA study. J Intern Med. 2006;260:551–9.

Article  CAS  PubMed  Google Scholar 

Franklin SS, Gustin IVW, Wong ND et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation. 1997;96:308–15.

Article  CAS  PubMed  Google Scholar 

Leiherer A, Brozek W, Muendlein A et al. The value of earlier-in-life systolic and diastolic blood pressure for cardiovascular risk prediction. iScience. 2024;27:109097.

Article  PubMed  PubMed Central  Google Scholar 

Leiherer A, Ulmer H, Muendlein A et al. Value of total cholesterol readings earlier versus later in life to predict cardiovascular risk. EBioMedicine. 2021;67:103371.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Allen N, Berry JD, Ning H, Van Horn L, Dyer A, Lloyd-Jones DM. Impact of Blood Pressure and Blood Pressure Change during Middle Age on the Remaining Lifetime Risk for Cardiovascular Disease: The Cardiovascular Lifetime Risk Pooling Project. Circulation. 2012;125:37.

Article  PubMed  Google Scholar 

Postmus I, Deelen J, Sedaghat S et al. LDL cholesterol still a problem in old age? A Mendelian randomization study. Int J Epidemiol. 2015;44:604–12.

Article  PubMed  Google Scholar 

Engebretsen I, Munkhaugen J, Bugge C et al. Gaps and discontinuation of statin treatment in Norway: potential for optimizing management of lipid lowering drugs. Eur Heart J Open. 2022;2(6):oeac070.

Article  PubMed  PubMed Central  Google Scholar 

Ray KK, Molemans B, Schoonen MW et al. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev Cardiol. 2021;28:1279–89.

Article  PubMed  Google Scholar 

Siostrzonek P, Brath H, Zweiker R et al. Lipid lowering therapy in primary and secondary prevention in Austria: are LDL‑C goals achieved?: Results from the DA VINCI study. Wien Klin Wochenschr. 2022;134:294–301.

Article  CAS  PubMed  Google Scholar 

Kotseva K, De Backer G, De Bacquer D et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019;26:824–35.

Article  PubMed  Google Scholar 

Banach M, Penson PE. Adherence to statin therapy: it seems we know everything, yet we do nothing. Eur Heart J Open. 2022;2(6):oeac071.

Article  PubMed  PubMed Central  Google Scholar 

De Backer G, Jankowski P, Kotseva K et al. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019;285:135–46.

Article  PubMed  Google Scholar 

Catapano AL, Graham I, De Backer G, et al. ESC/EAS Guidelines for the Management of Dyslipidaemias. Atherosclerosis. 2016;2016(253):281–344.

Article  Google Scholar 

Bellosta S, Corsini A. Statin drug interactions and related adverse reactions: an update. Expert Opin Drug Saf. 2018;17:25–37.

Article  CAS  PubMed  Google Scholar 

Kellick KA, Bottorff M, Toth PP. A clinician’s guide to statin drug-drug interactions. J Clin Lipidol. 2014;8:S30–S46.

Article  PubMed  Google Scholar 

Burger AL, Beran N, Pogran E et al. Low-density lipoprotein cholesterol reduction with immediate combination therapy of statin and ezetimibe compared to statin monotherapy after percutaneous coronary intervention. Wien Klin Wochenschr. 2023;135:674–9.

Article  CAS  PubMed  Google Scholar 

Sabatine MS, Giugliano RP, Keech AC et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376:1713–22.

Article  CAS  PubMed  Google Scholar 

Schwartz GG, Steg PG, Szarek M et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379:2097–107.

Article  CAS  PubMed  Google Scholar 

Sekkarie A, Park S, Therrien NL et al. Trends in Lipid-Lowering Prescriptions: Increasing Use of Guideline-Concordant Pharmacotherapies, U.S. Am J Prev Med. 2023;64:561–566.

Article  PubMed  Google Scholar 

Drexel H, Saely CH, Fibrates AS. One more lost paradise in lipid treatment. Eur Heart J Cardiovasc Pharmacother. 2023;9:121.

Article  PubMed  Google Scholar 

Drexel H, Tamargo J, Kaski JC et al. Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease? Eur Heart J Cardiovasc Pharmacother. 2023;9(6):570–582.

Article  PubMed  Google Scholar 

Lee Y, Shin J, Kim Y, Kim DS. Consumption of single products versus fixed-dose combination medicines for hypertension and hyperlipidemia during 2015–2019 in South Korea. PLoS ONE. 2021;16(12):e0259467.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guglielmi V, Bellia A, Pecchioli S et al. Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: A real-world evidence study in primary care. Atherosclerosis. 2017;263:36–41.

Article  CAS  PubMed  Google Scholar 

Neumann FJ, Sechtem U, Banning AP, et al. ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2019;2020(41):407–77.

Google Scholar